Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hepatitis B virus surface L protein related peptide

A hepatitis B and protein technology, applied in the direction of viral peptides, antiviral agents, peptide/protein components, etc.

Active Publication Date: 2012-07-04
SHANGHAI HEP PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] 2. Current status of prevention and treatment of HBV infection
In addition, other adverse reactions such as antigen-antibody complex immunopathology may also occur

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hepatitis B virus surface L protein related peptide
  • Hepatitis B virus surface L protein related peptide
  • Hepatitis B virus surface L protein related peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] Example 1: Inhibition of HBV hepatocyte infection by peptides derived from HBV surface L protein of B genotype adw serotype and C genotype adr serotype

[0086] 1. Preparation of peptides derived from surface L protein of HBV serotype B genotype adw serotype and C genotype adr serotype

[0087] N-terminal myristoyl-modified HBV surface L protein-derived peptides of B genotype adw serotype and C genotype adr serotype (SEQ ID NO: 3 amino acid glycine modified with myristoyl, expressed as Myr13-59) as AB431A According to the standard Fmoc protocol, using 0.25mM HMP as the starting resin, the peptide synthesizer is extended and synthesized residue by residue from the carboxy-terminus to the amino-terminus. To enhance the stability of the polypeptide, the C-terminus of the polypeptide was further amidated. After peptide synthesis, cut with cutting solution, filter out resin with G6 glass sand funnel, and vacuum dry the filtrate. Ion-free water dissolves peptide cleavage pr...

Embodiment 2

[0097] Example Two: Inhibition of HBV Hepatocyte Infection by Peptides Derived from Surface L Protein of D Genotype Ayw Serotype HBV Virus

[0098] 1. The synthesis of Myr2-47 (SEQ ID NO: 9) derived from surface L protein of HBV serotype D ayw serotype D with myristoyl modification (SEQ ID NO: 9) and the culture of primary human hepatocytes are the same as in Example 1.

[0099] 2. Cultivation of D genotype ayw serotype HBV virus

[0100] The 2.2.15 cell line, which can secrete complete D genotype ayw serotype HBV infected virus particles, was continuously cultured for 10 days. The culture supernatant was collected, centrifuged with 6% polyethylene glycol (PEG8000) to precipitate virus particles, the pellet was resuspended in phosphate buffer containing 25% fetal calf serum, and frozen at -80°C.

[0101] 3. Detection of HBsAg in hepatocyte culture supernatant after HBV infection (same as embodiment one)

[0102] 4. Inhibition of HBV surface L protein-derived peptide Myr2-47 ...

Embodiment 3

[0104] Example 3: Screening of HBV surface L protein derivatized peptides

[0105] 1, B genotype adw serotype and C genotype adr serotype HBV virus genotype serotype determination, virus culture, cultivation of human primary hepatocytes (same example 1).

[0106] 2. The construction of a recombinant plasmid carrying a complete HBV genome and having the complete replication ability of HBV.

[0107] Add 50 μl of HBV virus culture suspension to 310 μl proteinase K lysate [1mg / ml proteinase K, 50mmol / L Tris-HCl (pH8.0), 200mmol / L NaCl, 10mmol / L EDTA, 2% SDS, 1μg / ml poly(A) ]. After lysis at 60°C for 1 hour, extract with phenol / chloroform, precipitate with ethanol, and dissolve the precipitate in H 2 O is HBV DNA solution. Entire EN II replication element was amplified with upstream primer (Pst I) 5'ctgactgcagCACTGGATGGGGCTTGGCTATTGG (SEQ ID NO:21, 1202-1225) and downstream primer (EcoR I) 5'ttatggaattcCGACGCGGCGATTGAGACCTTC (2201-2180, SEQ ID NO:22). C genotype adr serotype HB...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention relates to peptides derived from HBV L protein for the prevention and treatment of Hepatitis B virus (HBV) infection, screening method for removing antigenicity of these peptides and the deantigenic derivative peptide screened through the method, wherein the HBV surface L protein pre-S1 region contains key amino acid sequence of the virus adhesion cell surface acceptor and antigenicamino acid sequence bonding with the anti-L protein antibody. The polypeptides at the HBV surface L protein pre-S1 region can suppress HBV infection to cells. The invention also provides the screening method for removing the antigenicity of these polypeptides.

Description

technical field [0001] The present invention relates to HBV surface L protein-derived peptides for preventing and treating hepatitis B virus (human hepatitis B virus, HBV) infection, a screening method for removing the antigenicity of these polypeptides, and the deantigenic derived peptides obtained by screening through the method. In particular, the present invention relates to L protein pre-S1 region polypeptides derived from HBV of B genotype adw serotype, C genotype adr serotype and D genotype ayw serotype HBV. Also in particular, the present invention relates to a screening method for removing the antigenicity of the HBV surface L protein-derived peptide and the HBV surface L protein-derived antigenic peptide obtained by the method, which can block HBV infection but does not bind to antibodies. The antigen-removing derivative peptide can cooperate with the anti-HBV surface L protein antibody to inhibit HBV infection. Background technique [0002] 1. Epidemiology of HBV...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/01G01N33/68A61K38/16A61P1/16A61P31/20
Inventor 刘宏利汪裕尹颖
Owner SHANGHAI HEP PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com